This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Nebraska
Licensed Nebraska practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Nebraska buyers need their own professional license and NPI; the wholesale drug distributor license is the supplier’s obligation, not the purchaser’s.
Nebraska is unusually centralized. The Uniform Credentialing Act places every health profession under the Department of Health and Human Services, with boards acting on a recommendation basis, and the wholesale drug distributor license sits with the same department’s Licensure Unit. Nebraska also has a Stem Cell Research Act on the books, and it is worth knowing that it funds research rather than authorizing any clinical service.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Nebraska? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from Nebraska
ExaVeyra ships to licensed practices in all 50 states, Nebraska included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Nebraska professional license in good standing, verifiable through the DHHS license lookup that covers every profession credentialed under the Uniform Credentialing Act.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Nebraska resale or exempt sale certificate (Form 13) filed with the Department of Revenue if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Nebraska licenses wholesale drug distributors through the DHHS Licensure Unit under the Wholesale Drug Distributor Licensing Act, with a separate license for each facility engaged in wholesale drug distribution in the state. The regime covers prescription drugs, and following the federal Drug Supply Chain Security Act, Nebraska no longer requires a state license from a manufacturer distributing only its own human prescription drugs in finished dosage form or from a third-party logistics provider. Notably there is no standalone pharmacy board issuing this license; it runs through the same department that credentials the professions. The license sits with the distributor, not with the purchasing practice.
Neb. Rev. Stat. §§ 71-7427 to 71-7463; 172 NAC 131 · Nebraska Department of Health and Human Services, Division of Public Health, Licensure Unit
Nebraska regenerative-medicine law
Nebraska has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Nebraska does have stem cells in its statute books, which causes regular confusion. The Stem Cell Research Act, sections 71-8801 to 71-8806 of the Nebraska Revised Statutes, enacted in 2008 as LB 606, creates an advisory committee and a grant program that matches, dollar for dollar up to five hundred thousand dollars per fiscal year, outside funds raised for nonembryonic stem cell research, and section 71-8806 bars state facilities and state funds from being used to destroy human embryos for research. None of that authorizes or conditions any clinical service. Practice in this area is governed by the Uniform Credentialing Act, the practice acts under it, and the boards that advise DHHS, alongside federal law.
How this applies to exosomes
Nebraska has not enacted a stem cell practice authorization like Florida, Texas, or Georgia, a disclosure law like California, or a documentation statute like Tennessee. The Stem Cell Research Act is sometimes cited as though it were a practice law; it funds nonembryonic stem cell research and restricts what state money may be used for, and it says nothing about who may administer anything to a patient. There is therefore no Nebraska definition to read exosomes into or out of, and exosomes are acellular extracellular vesicles rather than stem cells in any case. Exosome products in Nebraska are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Nebraska practice
Because nurse practitioners past the transition period hold independent authority, Nebraska supports two workable structures: an NP-led practice that evaluates and orders within its own scope, and a physician-led practice that delegates conventionally. The practical feature to plan around is that every license involved, physician, PA, NP, and RN, is issued by the same department, DHHS, so verification and any filing all run through one agency rather than several boards.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians are credentialed by DHHS on the recommendation of the Board of Medicine and Surgery under the Uniform Credentialing Act, may perform medical acts within their scope, and are the source of any delegation to staff who do not hold independent authority. |
| NP / APRN | Nebraska nurse practitioners hold full practice authority. LB 107 in 2015 removed the integrated practice agreement, and under section 38-2322 a nurse practitioner practices without a transition-to-practice agreement once the initial 2,000 hours of practice under a supervising provider are complete. Nurse practitioner practice under section 38-2315 includes diagnosis, treatment, and management of common health problems and acute and chronic conditions. |
| PA | Physician assistants practice under a collaborative agreement with a supervising physician under section 38-2050. Supervision is continuous but does not require the physical presence of the physician at the time and place services are rendered, and one physician may supervise no more than four physician assistants at a time absent a board waiver. |
| RN | Registered nurses may perform delegated treatments within their scope and under an order from a provider with authority to issue one. An RN does not evaluate the patient or set the treatment plan. |
Good faith examination
Nebraska expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. A nurse practitioner past the transition-to-practice period can be that provider. Confirm current expectations with the DHHS Licensure Unit and the relevant board, since this area is governed by the practice acts and board interpretation rather than a single statute.
Ownership and clinic licensing
Nebraska structures professional practice through its professional entity statutes, under which ownership of a professional corporation is limited to individuals licensed to render the same professional service, and courts and regulators expect clinical judgment to stay with licensees. The doctrine is not codified as a single bright-line prohibition of the Texas or New York kind, so management arrangements are common and the details matter. Structure ownership with Nebraska counsel before opening.
Cold chain into Nebraska
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Nebraska order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Omaha | Douglas | Largest Nebraska market, with the state’s deepest aesthetic and clinical coverage. |
| Lincoln | Lancaster | Capital and university market with a growing med spa segment. |
| Bellevue | Sarpy | Served alongside Omaha on the same metro lane. |
| Grand Island | Hall | Central Nebraska hub serving practices along the Platte corridor. |
| Kearney | Buffalo | Regional medical center market for south-central Nebraska. |
- Nebraska orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot-specific Certificate of Analysis.
Practice types we supply in Nebraska
Nebraska licensing and verification
Nebraska DHHS Licensure Unit, Medicine and Surgery
Physician and PA credentialing, on the recommendation of the Board of Medicine and Surgery.
Nebraska DHHS Licensure Unit, Nursing
RN and APRN licensing, with prescriptive authority granted to nurse practitioners at licensure.
Nebraska DHHS Licensure Unit, Wholesale Drug Distributor Licensing
Issues the wholesale drug distributor license that suppliers shipping into Nebraska hold.
Nebraska Department of Revenue
Sales tax registration and the Form 13 resale or exempt sale certificate.
Nebraska sourcing questions
- Does Nebraska have a stem cell law?
- Not a practice law. The Stem Cell Research Act, Neb. Rev. Stat. 71-8801 to 71-8806, creates an advisory committee and a matching grant program for nonembryonic stem cell research, and bars state facilities and funds from being used to destroy human embryos for research. It is a research funding statute, regularly mistaken for a clinical one, and it neither authorizes nor restricts any clinical service.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, in Nebraska or anywhere else, and the FDA has issued a public safety notification on exosome products. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot documentation on every vial.
- Can a nurse practitioner run a practice in Nebraska without a physician?
- Yes, once past the transition-to-practice period. LB 107 removed the integrated practice agreement in 2015, and under Neb. Rev. Stat. 38-2322 a nurse practitioner practices without a transition-to-practice agreement after the initial 2,000 hours of practice under a supervising provider. An NP-led practice then evaluates and orders within its own scope.
- Who licenses health professionals in Nebraska?
- One department. The Uniform Credentialing Act places physicians, physician assistants, nurses, and the other health professions under DHHS, Division of Public Health, with boards such as the Board of Medicine and Surgery acting on a recommendation basis. License verification for every profession runs through the same DHHS lookup.
- Does my Nebraska clinic need a wholesale drug distributor license to buy exosomes?
- No. The wholesale drug distributor license under the Wholesale Drug Distributor Licensing Act is held by the distributor shipping into Nebraska, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- How do physician assistants practice in Nebraska?
- Under a collaborative agreement with a supervising physician, per Neb. Rev. Stat. 38-2050. Supervision is continuous but does not require the physician’s physical presence, a PA may work at a site geographically remote from the physician, and one physician may supervise up to four PAs absent a board waiver.
- How long does cold-chain shipping take to Nebraska?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Nebraska DHHS, wholesale drug distributor licensing (accessed 16 October 2026)
- Neb. Rev. Stat. § 71-7427, Wholesale Drug Distributor Licensing Act (accessed 16 October 2026)
- Neb. Rev. Stat. § 71-8801, Stem Cell Research Act (accessed 16 October 2026)
- Neb. Rev. Stat. § 71-8806, state facilities and funds; restrictions (accessed 16 October 2026)
- Neb. Rev. Stat. § 38-2322, nurse practitioner transition-to-practice (accessed 16 October 2026)
- Nebraska DHHS, medicine and surgery licensing (accessed 16 October 2026)
- Nebraska Department of Revenue (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark characterization standard for extracellular vesicles, the baseline this page assumes when it describes what a defensible exosome COA and lot documentation package reports.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The current revision of the MISEV standard, supporting this page’s point that EV characterization expectations come from the field’s consensus guidelines rather than from any Nebraska statute.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products, the context for this page’s statement that no exosome product holds FDA approval.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.